

XVIVO Perfusion - Consensus estimates Q1 2024

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 6 (all of which have been updated or confirmed before the report)

KPI	Q1 2024E
Net sales (MSEK)	165
Organic growth in local currency (%)	15.8
Gross profit (MSEK)	123
EBIT (MSEK)	9
EBITDA (MSEK)	26
Net profit (MSEK)	8
Earnings per share (SEK)	0.25
Net sales per segment:	
Thoracic (MSEK)	103
Abdominal (MSEK)	40
Services (MSEK)	22

XVIVO Perfusion's Q1 report will be released on Wednesday, 24 April, at 07:30 am CEST.